Isoniazid: Nursing Drug Guide, Hepatotoxicity & NCLEX Review
Healthcare medication guide: monthly hepatitis surveillance, transaminase monitoring in adults 35+, empty-stomach dosing, pyridoxine for neuropathy prevention, and never giving isoniazid alone for active tuberculosis.
Isoniazid-associated hepatitis may occur even after many months of therapy. Risk increases with age (highest roughly ages 50–64 per labeling estimates), daily alcohol use, chronic liver disease, and injection drug use. Interview patients monthly; measure AST/ALT before therapy and periodically in persons 35 and older. Discontinue promptly when prodromal symptoms or signs of hepatic damage appear—continued use can cause a more severe liver injury. Preventive therapy should be deferred in acute hepatic disease.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm active TB is on a multidrug regimen (not INH alone), review alcohol use and prodromal symptoms (anorexia, nausea, dark urine, jaundice), and check latest AST/ALT in at-risk adults. Mild transaminase elevation may resolve, but symptoms plus rising enzymes mean hold isoniazid and contact the prescriber the same shift.
Most common brand names
Isoniazid (INH) is the generic antimycobacterial cornerstone for tuberculosis treatment and latent infection prevention.
Supplied as isoniazid tablets (commonly 100 mg and 300 mg). It is combined with agents such as rifampin, ethambutol, and pyrazinamide in institution-specific multidrug tuberculosis protocols per susceptibility and local formulary.
Why we give it — Indications
Isoniazid is recommended for all forms of drug-susceptible tuberculosis and for preventive therapy in selected high-risk tuberculin reactors. Active tuberculosis must never be treated with isoniazid alone—multidrug therapy prevents resistance.
| Use | Detail |
|---|---|
| Active tuberculosis (combination therapy) | Used with other effective antituberculosis drugs per susceptibility testing. Typical adult daily dose: 5 mg/kg up to 300 mg once daily, or 15 mg/kg up to 900 mg two or three times weekly under directly observed therapy (DOT). |
| Latent TB infection (preventive therapy) | After excluding active disease, adults >30 kg commonly receive 300 mg once daily for the prescribed duration (often 6–9 months per guideline). Positive Quantiferon TB Gold or tuberculin skin test with risk assessment guides initiation. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Isoniazid inhibits synthesis of mycolic acids, an essential component of the mycobacterial cell wall. At therapeutic levels it is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis. Resistant bacilli emerge rapidly with monotherapy—nurses must verify companion antituberculosis agents on every MAR pass.
Dosing overview
Dosing depends on whether the patient has active tuberculosis or latent infection, and whether daily or intermittent DOT regimens are used. Confirm weight for mg/kg calculations and distinguish treatment from preventive therapy.
Missed dose: If a dose is missed, follow institutional tuberculosis DOT protocol. Do not double the next dose without prescriber or pharmacist guidance. Document missed doses because nonadherence drives resistance and treatment failure.
Before you give it — Safety check
Pretreatment checks
- Confirm active TB is not being treated with isoniazid monotherapy—verify companion drugs on the MAR.
- Baseline AST/ALT before starting therapy in persons 35 and older and in other high-risk groups (daily alcohol, chronic liver disease, injection drug use, HIV, pregnancy/postpartum per protocol).
- Review allergies, alcohol use, neuropathy risk, and whether pyridoxine prophylaxis is ordered for at-risk patients.
Contraindications
- Severe hypersensitivity reactions, including drug-induced hepatitis.
- Previous isoniazid-associated hepatic injury; severe adverse reactions such as drug fever, chills, or arthritis.
- Acute liver disease of any etiology (defer preventive therapy).
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Daily alcohol | Higher incidence of isoniazid hepatitis per boxed warning and precautions. | Document alcohol counseling; reinforce hold rules for prodromal symptoms; consider more frequent monitoring per prescriber. |
| Phenytoin / carbamazepine / valproate | Isoniazid inhibits metabolism—serum anticonvulsant levels may rise (phenytoin intoxication risk). | Monitor drug levels and toxicity signs; prescriber adjusts anticonvulsant dose; use phenytoin cautiously in overdose management. |
| Acetaminophen / tyramine- or histamine-rich foods | Labeling reports severe acetaminophen toxicity with isoniazid and possible reactions to tyramine/histamine foods due to MAO-inhibiting activity. | Limit duplicate hepatotoxins; teach patients to report headache, flushing, or palpitations after certain foods; track total acetaminophen exposure. |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet (commonly 300 mg); IM/IV formulations may be available per formulary. Labeling states isoniazid should not be administered with food because bioavailability is reduced significantly when given with meals.
- Administer on an empty stomach when feasible — food significantly reduces bioavailability per labeling.
- Use DOT for twice-weekly or thrice-weekly regimens as recommended in prescribing information.
- Perform medication reconciliation so isoniazid is not duplicated across combination products and pyridoxine is not omitted.
Single-drug treatment of active tuberculosis is inadequate and leads to resistance. Verify at least one additional active antituberculosis agent is ordered, available, and tolerated before administering isoniazid for active disease.
Expected therapeutic response
- Gradual improvement in pulmonary symptoms (e.g., decreasing cough, improving energy) over weeks to months — not days.
- Negative or improving culture/smear data per laboratory protocol guides continuation (prescriber-led endpoint).
- Stable hepatic enzymes and absence of prodromal hepatitis symptoms on monthly review when monitoring is in place.
Red flags — Stop and act
Prodromal hepatitis symptoms may precede marked transaminase elevation. Treat patient reports seriously even when enzymes were previously normal.
- Unexplained anorexia, persistent nausea/vomiting, dark urine, or jaundice — hold isoniazid and notify prescriber promptly
- Persistent fatigue, weakness, or fever >3 days, especially with right upper quadrant abdominal tenderness
- AST/ALT greater than 3–5 times the upper limit of normal — discontinuation strongly considered per boxed warning
- New hand/foot paresthesias or worsening neuropathy despite therapy — review pyridoxine and notify prescriber
- Seizures, altered mental status, or intractable vomiting after suspected overdose — emergency escalation and IV pyridoxine per protocol
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Hepatitis / hepatotoxicity | Boxed warning — severe and sometimes fatal; most often first 3 months; age-related risk | Hold isoniazid; trend hepatic enzymes; notify prescriber same shift; do not restart without specialist plan |
| Peripheral neuropathy | Most common nervous system toxicity; dose-related; higher in slow acetylators | Assess tingling of hands/feet; confirm pyridoxine prophylaxis is active for at-risk patients |
| GI upset (nausea, vomiting, epigastric distress) | Reported in labeling | Supportive care; distinguish prodromal hepatitis from benign GI upset |
| Hypersensitivity (rash, fever, drug fever, lymphadenopathy) | Reported; may require permanent discontinuation | Stop drug at first hypersensitivity sign; do not rechallenge without specialist guidance |
| Hematologic (agranulocytosis, anemia, thrombocytopenia) | Reported | Review CBC trends; hold and notify for cytopenias per protocol |
| CNS (seizures, encephalopathy, psychosis — high dose) | Uncommon at conventional doses | Urgent escalation; consider overdose if acute ingestion suspected |
| Metabolic (hyperglycemia, metabolic acidosis — overdose) | Overdose-related | Activate emergency pathway; antidote is IV pyridoxine per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Specific incidence rates for individual adverse events beyond boxed-warning hepatitis estimates are not specified in the reviewed FDA prescribing information.
Overdose, toxicity, and antidote
Isoniazid overdose may present within 30 minutes to 3 hours with nausea, vomiting, dizziness, slurred speech, visual hallucinations, intractable seizures, metabolic acidosis, and coma. Gross ingestions of 80–150 mg/kg can be fatal without prompt treatment.
Management principles (prescribing information)
- Antidote: Intravenous pyridoxine (vitamin B6) on a gram-for-gram basis equal to the isoniazid dose when the ingested amount is known; if unknown, consider 5 g IV over 30–60 minutes in adults or 80 mg/kg in children.
- Seizures: Repeat pyridoxine if seizures continue; diazepam may be added; use phenytoin cautiously because isoniazid alters phenytoin metabolism.
- Decontamination: Activated charcoal and gastric emptying in the asymptomatic patient with airway protection per toxicology protocol.
- Supportive care: Ventilation, cardiac support, acidosis management, and dialysis only if seizures/acidosis are not controlled — per labeling and toxicology guidance.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- INH abbreviation—verify full drug name; do not confuse with insulin (historical high-risk abbreviation) or other one-word orders
- Isoniazid monotherapy—active tuberculosis requires multidrug therapy; hold and clarify if isoniazid is the only antituberculosis drug on the MAR
- Isoniazid vs isoniazid/rifampin fixed-dose combinations—double-check strength and whether companion drugs are included or ordered separately
- 100 mg vs 300 mg tablets—independent double-check and barcode scan when available; confirm total daily milligrams match weight-based calculation
- LTBI vs active TB dosing—preventive therapy is typically 300 mg daily in adults >30 kg; active disease may use intermittent higher mg/kg regimens under DOT
- Food timing error—labeling states isoniazid should not be given with food; document fasting administration when required
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | Give on an empty stomach when possible — food reduces bioavailability per labeling. DOT is standard for intermittent TB regimens. |
| Monthly review | Interview every patient at monthly intervals for hepatitis prodrome; age >35 and other risk groups need scheduled transaminase monitoring. |
| Pyridoxine | Confirm B6 is on the MAR for malnourished patients, alcohol use, diabetes, HIV, seizure disorders, renal failure, and pregnancy per protocol. |
| Diet teaching | Avoid tyramine-rich foods (aged cheese, red wine) and histamine-rich fish if patient reports headache, flushing, or palpitations — MAO-inhibiting activity per labeling. |
| Alcohol | Daily alcohol use increases hepatitis risk — document counseling and hold parameters per prescriber. |
| Commonly missed | Baseline AST/ALT before start in adults >35; attributing nausea to “normal TB meds” instead of hepatitis prodrome; giving with breakfast. |
| Ask pharmacy when | Drug interactions (phenytoin, carbamazepine, theophylline, valproate), rechallenge after hepatitis, or serum level questions in malabsorption/HIV. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Age >35 (especially 50–64) | Higher reported hepatitis case rates; baseline and periodic AST/ALT required in addition to monthly symptom interviews. |
| Daily alcohol / chronic liver disease / injection drug use | Boxed warning identifies these as major hepatitis risk factors — enhanced monitoring and low threshold to hold. |
| Women in postpartum period / minority groups per labeling | Labeling suggests increased fatal hepatitis risk in some groups — more frequent laboratory monitoring may be warranted per prescriber. |
| Pregnancy | Pregnancy Category C: embryocidal in animal studies; no adequate controlled human studies. Active tuberculosis during pregnancy should be treated because maternal benefit justifies fetal risk — regimen often isoniazid plus rifampin with ethambutol if needed; pyrazinamide data in pregnancy are limited per labeling. Preventive therapy is generally started after delivery when possible. |
| Lactation | Small concentrations in breast milk are not considered toxic to the nursing infant per labeling; breastfeeding need not be discouraged, but milk levels are insufficient for infant prophylaxis. LactMed should be consulted for updated guidance. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Monthly clinical interview for hepatitis prodrome in all patients; AST/ALT before therapy and periodically in persons 35 and older and other high-risk groups.
- Trend liver function tests and basic metabolic panel components per multidrug TB protocol.
- Neurologic symptom check for peripheral neuropathy; confirm pyridoxine adherence in at-risk patients; monitor drug levels when interacting anticonvulsants or theophylline are used.
Document
- Indication (active TB vs LTBI), weight-based dose, DOT observer, and companion antituberculosis drugs administered.
- Monthly symptom review, AST/ALT values, hold events, and prescriber notifications.
- Patient teaching on empty-stomach dosing, alcohol avoidance, prodromal hepatitis symptoms, and pyridoxine use.
Patient teaching
- Take isoniazid on an empty stomach unless your clinician advises otherwise — food reduces how much medicine is absorbed.
- Report right away: loss of appetite, nausea, vomiting, dark urine, yellow skin/eyes, unusual fatigue, abdominal pain, or numbness/tingling in hands and feet.
- Do not drink alcohol daily while on isoniazid unless your prescriber explicitly approves — alcohol increases liver injury risk.
- Take prescribed pyridoxine (vitamin B6) if ordered — do not skip it because you feel well.
- Finish the full course for LTBI or active TB; missing doses can lead to treatment failure and drug-resistant tuberculosis.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Any prodromal hepatitis symptoms (anorexia, nausea, vomiting, dark urine, jaundice, persistent fatigue, RUQ pain) or signs suggesting hepatic damage.
- AST/ALT exceeding 3–5 times the upper limit of normal per boxed warning — prescriber should strongly consider discontinuation.
- Acute liver disease, prior isoniazid hepatotoxicity, or hypersensitivity (rash with fever, drug fever, chills) unless specialist rechallenge plan exists.
- Active tuberculosis order shows isoniazid alone without companion antituberculosis drugs.
- Suspected acute overdose with seizures, altered mental status, or severe metabolic acidosis — hold and activate emergency/toxicology pathway for IV pyridoxine.
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Isoniazid nursing workflow centers on hepatotoxicity prevention across long treatment courses. Build liver surveillance into TB DOT visits the same way you would vitals for high-risk infusions.
1. Check-before-you-give protocol
- Right patient, indication (LTBI vs active TB), and dose (daily 300 mg vs weight-based intermittent regimen).
- Companion TB drug(s) due for active disease — not INH monotherapy.
- Ask about appetite, nausea, dark urine, jaundice, and alcohol use since last visit; review latest AST/ALT if on file.
- Confirm fasting administration when required and pyridoxine taken if ordered.
2. High-alert and safety badge
Boxed-warning surveillance medicationIsoniazid is not an ISMP high-alert drug, but the boxed warning for fatal hepatitis requires the same disciplined monitoring as high-risk therapy.
3. Clinical workflow: hold and question rules
- Hold and clarify if baseline transaminases are missing in a patient 35+ starting new therapy.
- Do not attribute worsening AST/ALT to companion drugs without prescriber review — multidrug attribution requires specialist input.
- Escalate same shift if patient reports prodromal symptoms even when enzymes are only mildly elevated.
4. Critical teach-back questions
- “What symptoms mean you should call the clinic immediately?” No appetite, nausea/vomiting, dark urine, yellow skin/eyes, severe fatigue, belly pain — especially right upper abdomen.
- “Can you take isoniazid with breakfast?” Not ideally — labeling says food reduces absorption; take on an empty stomach unless your team instructs otherwise.
5. Care coordination
Infectious diseases / TB clinic: Regimen selection, susceptibility results, LTBI vs active disease duration, and rechallenge decisions after hepatitis.
Pharmacy / hepatology: Drug interaction management, transaminase monitoring schedules, pyridoxine dosing, and overdose pyridoxine coordination.
🧠 Quick mental checklist
- Is this active TB on multidrug therapy — not INH alone?
- When were AST/ALT last checked in this patient 35+ or high-risk group?
- Any prodromal hepatitis symptoms or alcohol use since the last visit?
- Is pyridoxine on the MAR for neuropathy-prone patients?
- Is the patient taking isoniazid fasting as directed?
Isoniazid NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for isoniazid using a tabbed latent-TB case (MAR, labs, history, nursing notes), then work through priority action, hepatitis cue recognition, transaminase trend interpretation, matrix urgency sorting, pyridoxine judgment, and cloze overdose antidote therapy—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Isoniazid 300 mg PO daily — scheduled 0700 (fasting) — due now
- Rifampin 600 mg PO daily — companion LTBI regimen — due 0700
- Pyridoxine 25 mg PO daily — not on MAR (omitted at discharge)
- Acetaminophen 650 mg PRN headache — used twice yesterday
- Baseline AST 28 U/L, ALT 32 U/L (ULN 40 U/L) — week 0
- Week 2: AST 45 U/L, ALT 52 U/L — noted; therapy continued
- Week 6 (today): AST 185 U/L, ALT 210 U/L; total bilirubin 2.8 mg/dL
- Quantiferon TB Gold positive at intake; chest imaging without active disease
- 52-year-old started isoniazid + rifampin for latent TB after occupational exposure
- Reports 2–3 alcoholic drinks nightly — documented at start; no change counseled
- Type 2 diabetes; no prior neuropathy
- Week-6 symptoms: anorexia, nausea, dark urine — began 4 days ago
- 0645: Patient asks, “Is it normal to feel sick and my urine looks tea-colored?”
- 0650: Prior monthly visit documented “feeling fine” — no AST/ALT drawn at week 4 per flowsheet gap
- 0655: Nurse reviewing labs and history tabs before 0700 dose
- 0700: Patient usually takes isoniazid with morning toast — nurse verifying fasting instruction
Answer key & rationale
Frequently asked questions
What must nurses check before giving isoniazid?
Confirm active tuberculosis is on multidrug therapy (not INH alone), correct dose and indication (LTBI vs active TB), baseline and latest AST/ALT in patients 35+ and other high-risk groups, alcohol use, prodromal hepatitis symptoms, pyridoxine for at-risk patients, and fasting administration when required.
When should isoniazid be held?
Hold for prodromal hepatitis symptoms, jaundice, AST/ALT above 3–5 times ULN, acute liver disease, prior isoniazid hepatotoxicity, hypersensitivity, active TB orders missing companion drugs, or suspected overdose. Notify prescriber and pharmacy the same shift.
What adverse effects matter most with isoniazid?
Severe and sometimes fatal hepatitis (boxed warning) is the highest-stakes toxicity, usually in the first three months. Peripheral neuropathy is the most common nervous system effect; pyridoxine prevents it in at-risk patients. Also monitor for hypersensitivity, hematologic effects, and CNS toxicity especially in overdose.
What labs and vitals should be monitored on isoniazid?
Monthly symptom interviews for all patients; AST/ALT before therapy and periodically in persons 35 and older and high-risk groups (daily alcohol, chronic liver disease, injection drug use, HIV, postpartum per protocol). Many TB programs also track CBC and renal function on multidrug regimens.
What is the antidote for isoniazid overdose?
Intravenous pyridoxine (vitamin B6) on a gram-for-gram basis equal to the isoniazid dose when the amount ingested is known; if unknown, consider 5 g IV over 30–60 minutes in adults or 80 mg/kg in children per FDA prescribing information, with seizure and airway support. Contact local poison control per facility protocol.
References
-
U.S. National Library of Medicine. ISONIAZID tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9e6aa9e-c905-4774-b4d4-ae6acc2f64a1
-
U.S. Food and Drug Administration. Isoniazid Tablets, USP — Prescribing information (ANDA 008678).https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/008678s030lbl.pdf
-
Centers for Disease Control and Prevention. Treatment for Drug-Susceptible Tuberculosis Disease.https://www.cdc.gov/tb/hcp/treatment/tuberculosis-disease.html
-
Nahid P, Dorman SE, et al. ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. CDC guideline PDF.https://www.cdc.gov/tb/publications/guidelines/pdf/Clin-Infect-Dis.-2016-Nahid-cid_ciw376.pdf
-
Drugs and Lactation Database (LactMed). Isoniazid. Bethesda (MD): National Library of Medicine.https://www.ncbi.nlm.nih.gov/books/NBK501336/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.